Liver abnormalities in pulmonary arterial hypertension

Area of Science:

• Cardiology
• Hepatology
• Metabolic Diseases

Background:

• Pulmonary arterial hypertension (PAH) is a severe cardiopulmonary disease with high mortality.
• PAH is increasingly understood as a multi-organ system disease affecting circulation, kidneys, muscles, and the nervous system.
• Right heart failure in PAH leads to congestive hepatopathy, impacting liver function and metabolism.

Purpose of the Study:

• To summarize the consequences of congestive hepatopathy in PAH patients.
• To emphasize the effects on liver biochemistry and histology.
• To discuss PAH-targeted therapies and their relation to liver health and metabolic changes.

Main Methods:

• Literature review and synthesis of existing research on PAH, congestive hepatopathy, and metabolic alterations.
• Analysis of studies focusing on liver biochemistry and histology in PAH.
• Review of current and emerging PAH-targeted therapies.

Main Results:

• Congestive hepatopathy significantly alters liver biochemistry and histology in PAH patients.
• PAH is associated with distinct changes in systemic glucose and lipid metabolism.
• Understanding these multi-organ effects is crucial for comprehensive PAH management.

Conclusions:

• Congestive hepatopathy is a significant complication of PAH, affecting liver function and metabolism.
• PAH-targeted therapies must consider the multi-organ impact, including liver health.
• Further research is needed to elucidate the complex interplay between PAH, liver disease, and metabolic dysfunction.